Testimonials
Hear what our previous attendees & speakers have to say about the DDR, ATR & PARP Inhibitors Summit:
“Meeting for everyone involved in DDR drug research!”
Merck & Co
“There really isn’t another conference like this mainly focused on PARP and DDR translational research.”
EMD Serono
“DDR inhibitors represent the next generation of cancer therapeutics and present the possibility of the benefits of targeted therapy with applications across various tumor types. Despite the obvious success and rapid development in this field, there are multiple areas for improvement as well as a plethora of areas for true innovation in the field. This meeting will provide the opportunity to explore these important topics.”
Katie Pawelczak, VP of Research, NERx Biosciences
“Hanson Wade’s DDR & PARPi summit is excellent & one of the very focused meetings that we look forward to attending ever year, where you can hear top-notch scientific discoveries and developments in DDR field, and a great opportunity to connect with experts in the field.”
Asli Muvaffak, Associate Director - Scientific, Oncology, Synthetic Lethality & Research Unit, GSK
“Great summary of the DDR field with interesting discussions and updates on latest data ”
Novartis
“This summit is the place to be for people developing DDR targeting drugs, to compare ideas with experts and be aware of all the advances around this hot topic.”
Wael JDEY, Lead Scientist, Onxeo
“The Hanson Wade PARP and DDR inhibitor summit provide a great opportunity to learn the landscape and focus of the DDR drug discovery field. Looking forward to an in-person meeting to have the opportunity to interact with experts and colleagues.”
Agios Pharma
“The “PARP & DDR Inhibitors Summit” brings together industry and clinical experts in the field of DNA Damage Response (DDR). Through my participation in the conference I aim to hear about and contribute to the latest advances in therapeutic targeting of the DDR in cancer (from basic science to clinical application). I am looking forward to attending the 4th PARP & DDR Inhibitors Summit which will help the scientific community to progress towards the discovery and development of novel therapies for cancer patients.”
Sotirios Soitriou, Head of Biology & Co-Founder, FoRx Therapeutics
“This is a very informative meeting with the right experts and relevant topics.”
Tango Therapeutics
“A great opportunity to connect with experts and leaders at the the forefront of DDR research, sparking collaboration and interest to move forward the next wave of DDR-focused anti-cancer agents”
Artios Pharmaceuticals
“I have over 30 years experience in the preclinical development and translational studies of DDR inhibitors. I want to use this experience to optimise their clinical use..”
Nicola Curtin, Professor of Experimental Cancer Therapeutics, Newcastle University
“This is a very unique meeting that brings together basic and translational scientists from academia and industry to discuss cutting-edge DNA repair science and how these discoveries can be translated into novel therapeutic approaches.”
Kent Mouw, Assistant Professor of Radiation Oncology, Dana-Farber Cancer Institute
“To listen to and share information that will benefit the DDR inhibitor therapeutic field for the benefit of patients.”
Mark O’Connor, Chief Scientist Oncology R&D, AstraZeneca
“A great opportunity to share thoughts with peers and competitors and get a deeper understanding of how the field is evolving.”
Ioannis Gounaris, Senior Medical Director, Cluster Lead DNA Damage Response (DDR) Inhibitors, Global Clinical Development Oncology Group II, Merck KGaA
“Very good and comprehensive package of what is currently known about opportunities and problems with drug development within DDR field.”
Orion Pharma
“Outstanding and robust conference bring together all the stake-holders in the PARP & DDR eco-system”
National Brain Tumor Society
“The Summit provided very high level talks emphasizing emerging biology and highest priority drug targets.”
Dana-Farber Cancer Institute
“Exceeded expectations”
Clovis Oncology
